May 26, 2026 Log in

clinical_trial_update

6550 Polaris Pharmaceuticals-KY Suspension of Phase III Clinical Trial for LMS

Citation-Grade Primary-source linked Schema.org verified NQ 48 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published May 26, 2026 6:31 AM ・ Updated Jun 14, 2026 12:07 AM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

Polaris Pharmaceuticals-KY announced the suspension of its Phase III clinical trial for ADI-PEG 20 in treating leiomyosarcoma (LMS), following recommendations from the Data Safety Monitoring Board (DSMB).
The company plans to optimize the trial design.

Polaris Pharmaceuticals-KY announced the suspension of its Phase III clinical trial for ADI-PEG 20 in treating leiomyosarcoma (LMS), following recommendations from the Data Safety Monitoring Board (DSMB). The company plans to optimize the trial design.

PRIMARY SOURCE Original source: https://openapi.twse.com.tw/v1/opendata/t187ap04_L#6550-1150526-ba8c3edf Distributor: PR Times
Published: May 26, 2026

On May 25, 2025, Polaris Pharmaceuticals-KY announced the decision to suspend its Phase III multi-center clinical trial of ADI-PEG 20 in combination with Gemcitabine and Docetaxel for the treatment of leiomyosarcoma (LMS). This decision follows a review by the Data Safety Monitoring Board (DSMB). The company will now focus on optimizing the patient population and trial design. There is no material impact on the company's financial or operational status at this time.

FACT BOX

Source: PR Times
Category: clinical_trial_update

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　May 26, 2026 6:31 AM — Distributor PR Times
Collected　May 26, 2026 6:31 AM
AI structured & analyzed　May 31, 2026 8:13 PM
Desk-reviewed & published　May 26, 2026 6:31 AM

FAQ

Why was the clinical trial suspended?

Based on DSMB recommendations to optimize the trial design.

What are the key facts in this article?

Where is the primary source?

PR Times: https://openapi.twse.com.tw/v1/opendata/t187ap04_L#6550-1150526-ba8c3edf

Cite this article — HOW TO CITE

Washin AI News Desk“6550 Polaris Pharmaceuticals-KY Suspension of Phase III Clinical Trial for LMS”AI News by Washin Village（和心村）, May 26, 2026. https://aeo.idaeo.ai/ai/openapi-twse-com-tw/en/news/2026-05-25-6550-%E5%8C%97%E6%A5%B5%E6%98%9F%E8%97%A5%E6%A5%AD-ky

AI CRAWLER ACTIVITY

as of Aug 18, 2026

AI crawler visits to this article (cumulative)41 bots

Site-wide cumulative

Applebot

bot_visits_summary

2838k

last Aug 18, 2026

GPTBot

bot_visits_summary

2063k

last Aug 18, 2026

ClaudeBot

bot_visits_summary

816k

last Aug 18, 2026

Bingbot

bot_visits_summary

772k

last Aug 18, 2026

Amazonbot

bot_visits_summary

622k

last Aug 18, 2026

Meta AI

bot_visits_summary

479k

last Aug 18, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← openapi-twse-com-tw Back to newsroom (21554)

Copied